PPT-Accelerating Progress towards Measles and Rubella Elimination

Hotel Royal Geneva Switzerland 2123 June 2016 Paul Rota Measles Mumps Rubella Herpesviruses Laboratory Branch CDC par1cdcgov National Center for Immunization amp Respiratory Diseases. . Accelerating Progress towards Measles/Rubella Control and Elimination Goals Meeting. Geneva, Switzerland. June 19, 2016. Lance Rodewald. WHO China Country Office. Measles and Rubella Vaccination Schedule. --Who We Are--. Stephen Cochi, . MD, MPH. Global . Immunization Division. Centers . for . Disease Control & Prevention. What is the Measles & Rubella Initiative? . Anne Ray Charitable Trust. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. B . Masresha. WHO . AFRO. June 2016. Outline. Regional goal. Routine immunisation . SIAs. Disease Surveillance. Plans for 2017 - 2018. Challenges . TA to countries. African Regional . goal: . Measles . Dr. Khin Devi Aung. Gavi Secretariat. 21. . June 2016, Geneva. 1. #. vaccineswork. AGENDA. About Gavi, the Vaccine Alliance. Gavi’s. support to countries. Gavi’s. 2016-2020 Strategy. Gavi’s. Elimination,. . 21-23 June 2016, Hotel Royal, Geneva. National Center for Immunization & Respiratory Diseases. Division of Viral Diseases. Joseph P. Icenogle, the CDC rubella Team, CDC colleagues, . 2020. . Summary of the . Findings . and Implementation Status . Dr Kaushik . Banerjee. M&RI Partners' Meeting. Washington DC. 7 September 2017. 1. Objectives . of . the Review. To provide a candid review of progress . South East Asia Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 66th Meeting of the SEAR Regional Committee in September 2013 in New Delhi resolved . to adopt . the goal of . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. Measles and Rubella Annual Partners Meeting, September 15-16 2015. Background. The MRI FRR is developed by the M&RI FRR/RMAWG. Country population data is drawn from UNDP estimates. Vaccine type and timing of SIAs is from countries . MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C Opening Comments & Perspectives. Dr. Suresh Jadhav. Executive Director. Serum Institute of India Pvt. Ltd.,. ssj@seruminstitute.com. . We, at Serum Institute of India Pvt. Ltd., feel proud of being a partner to PAHO / WHO in achieving what is designated to be a historical achievement in eradication of Measles & Rubella diseases from the Americas.. .. Education Department.. Kolkata. . Measles . - . An acute viral infection spread via respiratory secretions or aerosols. leading causes of death . among young children . even though a safe and cost-effective vaccine is available.